for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alexion Pharmaceuticals, Inc.

ALXN.O

Latest Trade

157.74USD

Change

-0.97(-0.61%)

Volume

3,717,827

Today's Range

157.26

 - 

159.10

52 Week Range

72.67

 - 

160.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
158.71
Open
159.10
Volume
3,717,827
3M AVG Volume
50.93
Today's High
159.10
Today's Low
157.26
52 Week High
160.03
52 Week Low
72.67
Shares Out (MIL)
218.72
Market Cap (MIL)
34,713.14
Forward P/E
13.10
Dividend (Yield %)
--

Next Event

Q4 2020 Alexion Pharmaceuticals Inc Earnings Release

Latest Developments

More

Alexion Provides Update On Phase 3 Study Of Ultomiris® In Hospitalized Patients With Severe Covid-19

Alexion Pharmaceuticals Says Expects To Exceed High End Of 2020 Revenue Guidance

Alexion Pharmaceuticals Says Co Will Pay Equal To $1.18 Bln To Astrazeneca, If Deal Terminated In Certain Circumstances

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Industry

Major Drugs

Contact Info

121 Seaport Blvd

BOSTON, MA

02210-2050

United States

+1.475.2302596

https://alexion.com/

Executive Leadership

David R. Brennan

Independent Chairman of the Board

Ludwig N. Hantson

Chief Executive Officer, Director

Aradhana Sarin

Executive Vice President, Chief Financial Officer

Indrani Franchini

Executive Vice President, Chief Compliance Officer

Ellen Chiniara

Executive Vice President, Chief Legal Officer. Corporate Secretary

Key Stats

2.72 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

3.6K

2018

4.1K

2019

5.0K

2020(E)

6.0K
EPS (USD)

2017

5.860

2018

7.920

2019

10.530

2020(E)

12.117
Price To Earnings (TTM)
37.17
Price To Sales (TTM)
5.92
Price To Book (MRQ)
3.14
Price To Cash Flow (TTM)
26.67
Total Debt To Equity (MRQ)
23.40
LT Debt To Equity (MRQ)
22.15
Return on Investment (TTM)
6.39
Return on Equity (TTM)
5.91

Latest News

Latest News

UPDATE 1-Alexion pauses enrollment for COVID-19 study testing its rare blood-disorder drug

Alexion Pharmaceuticals Inc on Wednesday paused enrollment in a late-stage study testing its rare blood-disorder drug in adults with severe COVID-19 requiring mechanical ventilation.

Alexion pauses enrollment for COVID-19 study testing its rare blood-disorder drug

Alexion Pharmaceuticals Inc on Wednesday paused enrollment in a late-stage study testing its rare blood-disorder drug in adults with severe COVID-19 requiring mechanical ventilation.

Wall St opens higher as travel stocks rally on vaccine roll-out

Wall Street's main indexes opened higher on Monday as travel stocks surged on the launch of a nationwide COVID-19 vaccine campaign, while Alexion Pharmaceuticals jumped following a bumper buyout offer from Britain's AstraZeneca.

AstraZeneca shares fall on "hefty" $39-billion Alexion deal

AstraZeneca shares fell as much as 9% on Monday, as investors moved to price in the costs of a $39 billion deal for U.S. biotech company Alexion Pharmaceuticals that would be the British drugmaker's biggest ever corporate acquisition.

Breakingviews - AstraZeneca’s $39 billion deal is bold as well as big

The largest acquisition in AstraZeneca’s history is bold as well as big. The British drugmaker on Saturday announced it is buying U.S biotech Alexion Pharmaceuticals, which makes treatment for a rare immune disease, for $39 billion in cash and stock. Competitive challenges...

AstraZeneca shares sink 8% after $39 billion Alexion buyout

Shares of AstraZeneca fell 8% early on Monday, hit by doubts about the British firm's strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals over the weekend.

AstraZeneca to buy Alexion for $39 billion to expand in immunology

Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.

AstraZeneca to acquire Alexion in $39 bln deal

Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

Roche gets U.S. approval for Enspryng, takes on Alexion's Soliris

The U.S. Food and Drug Administration on Saturday approved Roche's Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion's Soliris in a costly treatment area.

Alexion to pay $21.5 million to settle SEC foreign bribery probe

Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.

Alexion pays $21 million resolving charges of breaking U.S. foreign corruption law: SEC

Alexion Pharmaceuticals <ALXN.O> has agreed to pay $21 million to resolve U.S. charges that it violated a major anti-corruption law when two of its subsidiaries paid Turkish and Russian officials for favorable treatment of its Soliris drug, the top securities regulator said...

BRIEF-Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission

* ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Alexion Announces Phase 3 Study Of Weekly Subcutaneous Ultomiris Met Primary Endpoint

* ALEXION ANNOUNCES PHASE 3 STUDY OF WEEKLY SUBCUTANEOUS ULTOMIRIS® (RAVULIZUMAB-CWVZ) MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Activist investor Elliott pushes Alexion Pharma to sell itself

Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

Elliott again pushes Alexion Pharma to explore a sale

Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.

BRIEF-Elliott Advisors Sends Letter To Alexion Pharmaceuticals

* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE

BRIEF-Alexion Pharmaceuticals Sees FY Revenue $5,230 Mln To $5,330 Mln

* Q1 REVENUE $1.445 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.36 BILLION

BRIEF-Portola Pharmaceuticals Cancels Q1 Results Webcast And Conference Call Following Agreement To Be Acquired By Alexion

* PORTOLA PHARMACEUTICALS CANCELS FIRST QUARTER 2020 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL FOLLOWING AGREEMENT TO BE ACQUIRED BY ALEXION Source text for Eikon: Further company coverage:

Alexion bets on Portola's bleeding antidote with $1.41 billion deal

Alexion Pharmaceuticals Inc <ALXN.O> on Tuesday agreed to buy Portola Pharmaceuticals Inc <PTLA.O> in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up